Pediatric transplantation encompasses a wide range of life-saving procedures performed on children from infancy through adolescence, including solid organ transplants (heart, liver, kidney, lung, intestine) and hematopoietic stem cell transplants for blood disorders and cancers. While these procedures share the same broad goal as adult transplantation, nearly every aspect differs in practice. Children’s immune systems behave differently, their bodies are still growing, the organs they need are in even shorter supply than adult organs, and success means not just surviving years but developing into healthy adults. Those differences make pediatric transplantation its own field, with distinct challenges and, in some cases, surprising biological advantages.
Why Children Are Not Small Adults
The phrase gets repeated in pediatric medicine for good reason: the developing immune system operates by different rules than the adult version. Infants, for instance, have not yet begun producing antibodies against certain carbohydrate antigens, including the blood-group antigens that normally make ABO-incompatible transplants dangerous. This absence of preformed antibodies, combined with lower complement activation and reduced innate immune cell activity, means that certain transplants considered off-limits in adults can be performed safely in very young children.1PubMed Central. The immune system in infants: Relevance to xenotransplantation A landmark study in the New England Journal of Medicine demonstrated that ABO-incompatible heart transplants could be performed safely during infancy, before the baby starts making the antibodies that would otherwise trigger hyperacute rejection. The result was a substantial drop in waiting-list mortality for infant heart recipients, because the pool of available donor hearts effectively expanded when blood-type matching was no longer required.2PubMed. ABO-incompatible heart transplantation in infants
This tolerance window is not permanent. As children grow, their immune systems mature and begin producing the same anti-carbohydrate antibodies adults carry. Research using specialized tools to track how B-cell populations change with age has confirmed that the tendency toward tolerance rather than rejection has “exquisite specificity” and fades as the B-cell compartment and complement system develop.3PubMed. Neonatal tolerance: applicability to solid organ transplantation Interestingly, some children who received ABO-incompatible hearts as infants later develop donor-specific antibodies without suffering clinical consequences, suggesting that the mechanism of graft acceptance involves more than just the absence of antibodies and may include pathways beyond simple B-cell tolerance.4PubMed. Development of donor-specific isohemagglutinins following pediatric ABO-incompatible heart transplantation
Heart Transplantation in Children
Pediatric heart transplantation carries its own set of complexities that have little in common with the adult procedure. The two main reasons a child needs a new heart are cardiomyopathy (disease of the heart muscle itself) and congenital heart disease, and these diagnoses lead to very different surgical experiences. A child with complex congenital anatomy may have already undergone multiple open-heart surgeries, making the transplant technically demanding in ways that a straightforward adult transplant is not. Waitlist management, the surgical approach, and even immunosuppression protocols differ between children and adults.5PubMed Central. Pediatric heart transplantation
Outcomes also vary considerably depending on why the child needed a transplant. A single-center review spanning 24 years and over 300 patients found that survival was best in children transplanted for cardiomyopathy and worst in those with failed surgical repairs for single-ventricle heart defects, including failed Fontan procedures.6PubMed. Trends in the indications and survival in pediatric heart transplants: a 24-year single-center experience in 307 patients The children with congenital disease often arrive at transplantation sicker, with more scar tissue and altered anatomy from prior surgeries, which partially explains the gap.
Liver Transplantation and the Donor Problem
The shortage of size-matched donor organs is especially acute for infants and small children needing a liver. Unlike kidneys, where dialysis can keep a patient alive for years, there is no comparable bridge therapy for liver failure. Two main strategies have emerged to address the size mismatch: splitting a deceased donor liver so the smaller left lateral segment can be transplanted into a child, and using a living donor (usually a parent) who donates a portion of their liver.
Both approaches produce acceptable results, but they are not identical. An analysis of the U.S. national transplant database found that living-donor recipients had a lower rate of graft failure compared to those receiving split grafts, at roughly 10% versus 15%. The most common cause of graft failure in both groups was hepatic artery thrombosis, a known complication in small-caliber vessels. Still, overall patient and graft survival at one, three, and five years were comparable. In subgroup analyses, children who were very young or very small showed the clearest benefit from living-donor grafts.7Transplant International. Living Donor Liver Transplantation vs. Split Liver Transplantation Using Left Lateral Segment Grafts in Pediatric Recipients: An Analysis of the UNOS Database
Stem Cell Transplants for Non-Cancer Conditions
Hematopoietic stem cell transplantation, sometimes called bone marrow transplant, is curative for a wide range of non-malignant disorders in children. These include sickle cell disease, thalassemia, severe combined immunodeficiency, and other inherited immune and metabolic conditions.8PubMed. Transplant for non-malignant disorders: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee report on the role of alternative donors, stem cell sources and graft engineering A major barrier has always been finding a well-matched donor. When no matched sibling or unrelated donor is available, transplant teams increasingly turn to haploidentical donors, meaning a half-matched parent. To make this work safely, the graft is processed to remove certain immune cells that would otherwise cause severe graft-versus-host disease. One approach removes a specific subset of T cells and B cells, and a study of 20 such transplants in children with non-malignant diseases reported engraftment in 85% of cases. After a median follow-up of four years, cumulative survival was 90%, and the risk of serious graft-versus-host disease was very low.9PubMed. Haploidentical Stem Cell Transplantation After TCR-αβ(+) and CD19(+) Cells Depletion In Children With Congenital Non-Malignant Disease
The Immunosuppression Balancing Act
Every transplant recipient needs immunosuppressive drugs to prevent rejection, but in children the stakes of getting the dose wrong are amplified. Too little medication and the organ is rejected. Too much and the child faces infections, kidney damage, and a specific complication that is far more relevant in pediatric patients than adults: impaired growth. Because children are expected to live decades with their transplanted organs, the cumulative effects of long-term drug toxicity matter far more than in a patient who receives a transplant at age 60.10PubMed. Therapeutic drug monitoring in pediatric renal transplantation
Drug monitoring in children is further complicated by the fact that kids metabolize these medications differently at different ages. The relationship between a drug’s trough blood level and its actual exposure in the body can shift as a child grows, meaning that a dose that was correct at age five may be dangerously high or low at age eight without any obvious clinical change.11PubMed. Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients
Growth, Puberty, and the Problem With Steroids
Corticosteroids have been a mainstay of anti-rejection therapy since transplantation began, but they take a particular toll on growing bodies. A systematic review and meta-analysis of studies across both kidney and liver transplant recipients found that withdrawing or avoiding steroids was associated with a measurable improvement in height in renal transplant patients. The effect was most pronounced in prepubertal children. Importantly, steroid withdrawal did not increase the risk of acute rejection, graft failure, or death in the renal transplant trials.12PubMed Central. Corticosteroid Use and Growth After Pediatric Solid Organ Transplantation: A Systematic Review and Meta-Analysis
A long-term study of pediatric liver transplant recipients confirmed that those still receiving steroids at their most recent follow-up were more likely to have growth impairment. The authors advocated for more aggressive steroid-withdrawal protocols or steroid-free regimens, noting that such approaches had already been shown to improve linear growth.13PubMed Central. Long-Term Linear Growth and Puberty in Pediatric Liver Transplant Recipients Beyond height, immunosuppressive therapy can delay or disrupt puberty and affect fertility. The psychological consequences of being visibly shorter or physically less developed than peers during adolescence can erode self-esteem, reduce quality of life, and, critically, damage the teenager’s willingness to keep taking the very medications that are causing the problem.14Pediatric Transplantation. Immunosuppressive Therapy, Puberty and Growth Outcomes in Pediatric Kidney Transplant Recipients: A Pragmatic Review
Complications Unique to Children
Graft-versus-host disease remains a leading cause of illness and death after stem cell transplant in children. Only about 30% to 50% of children respond to corticosteroids as first-line therapy, and the optimal second-line treatment has not yet been clearly established.15PubMed Central. Management of acute graft-versus-host disease in children
On the solid organ side, one of the most concerning complications in pediatric recipients is post-transplant lymphoproliferative disorder, or PTLD, a type of abnormal cell growth driven primarily by Epstein-Barr virus. Children are particularly vulnerable because many are EBV-naïve at the time of transplant, meaning they have never encountered the virus before. When they receive an organ from an EBV-positive donor, the mismatch creates a substantially higher risk. A prospective multicenter U.S. study found that the combination of an EBV-seropositive donor and an EBV-naïve recipient was the single most significant risk factor for developing PTLD, nearly tripling the hazard compared to other donor-recipient combinations.16Pediatric Transplantation. Epstein–Barr virus‐associated post‐transplant lymphoproliferative disorders in pediatric transplantation: A prospective multicenter study in the United States Separately, higher tacrolimus levels before the onset of EBV viremia have been linked to PTLD development, underscoring the connection between heavy immunosuppression and this complication.17PubMed Central. Post-Transplant Lymphoproliferative Diseases in Pediatric Kidney Allograft Recipients with Epstein-Barr Virus Viremia
Cognitive and Psychosocial Outcomes
Saving a child’s life with a transplant is the first goal, but the years that follow reveal a subtler challenge: transplanted children often face cognitive and psychosocial difficulties that can persist into adolescence and beyond. Children who undergo liver transplantation, for example, score significantly lower across multiple cognitive domains compared to healthy peers. One study found that their rate of “serious delays,” defined as an IQ below 70, was roughly twice as high as in the general population, and that the child’s underlying diagnosis and how sick they were at the time of transplant predicted long-term cognitive outcomes.18PubMed. Cognitive performance in pediatric liver transplant recipients
A separate study testing liver transplant recipients at a median of about four years post-transplant found a mean full-scale IQ of roughly 92, lower than the population average of 100. In patients tested more than once over time, scores did not improve, suggesting that the cognitive gap is stable rather than something children grow out of.19The Journal of Pediatrics. Neurocognitive Development and Executive Function after Pediatric Liver Transplantation Among adolescent liver transplant recipients, over half of parents reported poor school and cognitive functioning in their children, and the adolescents themselves rated their psychosocial and school functioning worse than healthy peers. These deficits appear to reflect attention and executive function problems more than global intellectual disability, and they did not improve over time.20Liver Transplantation. Health‐Related Quality of Life and Cognitive Functioning in Pediatric Liver Transplant Recipients
The Adolescent Adherence Crisis
Teenagers are, statistically, the hardest transplant patients to keep on their medications. Adolescence brings a desire for normalcy, peer pressure, risk-taking behavior, and sometimes active rebellion against a medical routine that has defined their entire childhood. A systematic review of psychosocial predictors found that non-adherence was associated with adolescence itself, racial and ethnic minority status, mental health issues, single-parent households, lower socioeconomic status, family conflict, and the social pressures of wanting to “feel normal” among peers.21Pediatric Transplantation. Psychosocial predictors of medication non‐adherence in pediatric organ transplantation: A systematic review Despite the well-documented risks, intervention research designed to actually improve adherence in this population remains scarce.22PubMed Central. Medical adherence in pediatric organ transplantation: what are the next steps?
The transition from pediatric to adult care is a related danger zone. A study comparing different transition models for kidney transplant recipients found that a dedicated transition clinic was associated with fewer medication changes and higher patient satisfaction than simply transferring to an adult provider. However, kidney function one year after the switch was similar regardless of the model used.23Pediatric Transplantation. Different models of transition to adult care after pediatric kidney transplantation: A comparative study A national-level study went further, finding that implementing a formal transition model had no measurable effect on patient or graft survival at ten years, with graft survival hovering around 60% in both eras.24Clinical Transplantation. Implementation of a transition model to adult care may not be enough to improve results: National study of kidney transplant recipients The implication is sobering: structured transition programs improve the experience of care but may not, by themselves, solve the deeper behavioral and social factors that cause young adults to lose their grafts.
Vaccination Before and After Transplant
Vaccinations are a surprisingly fraught area for transplant families. Children headed for transplant are often too young to have completed their routine immunization schedule, and those who are already chronically ill may have missed doses. After transplant, the immunosuppressive drugs that protect the new organ also weaken the immune response to vaccines. Live-attenuated vaccines, like measles-mumps-rubella and varicella, are generally considered risky in immunosuppressed patients, though the reality is more nuanced than a blanket prohibition.25PubMed Central. Vaccinations in Paediatric Solid Organ Transplant Candidates and Recipients
One study of pediatric liver transplant recipients found that live-attenuated vaccines could be administered safely and effectively to children who were not severely immunosuppressed, though the protection rate after a first dose of measles, mumps, and varicella vaccines was lower than in healthy children.26PubMed. Effectiveness and safety of immunization with live-attenuated and inactivated vaccines for pediatric liver transplantation recipients A systematic review focused on varicella vaccination in pediatric solid organ transplant recipients found that about 88% seroconverted after vaccination, with no cases of vaccine-strain varicella and fewer than 1% developing actual varicella disease. Most studies followed criteria like waiting at least a year after transplant and ensuring the child was on low-dose immunosuppression.27PubMed. Safety and immunogenicity of the live-attenuated varicella vaccine in pediatric solid organ transplant recipients: A systematic review and meta-analysis The practical message for families: getting as many vaccinations done as possible before transplant is the strongest strategy, and post-transplant vaccination should be carefully timed rather than avoided entirely.
Allocation Ethics and the Question of Priority
Should children receive priority access to donor organs? The question seems straightforward until you try to defend the answer. A scoping review of the ethical literature found arguments both for and against child-priority rules, organized around three themes: equal treatment of individuals, individual benefit, and social benefit. Those favoring priority argue that children have the most life-years to gain and that society has a special obligation to protect the vulnerable. Those opposing it argue that age-based preference violates equal treatment principles and that defining an age cutoff creates arbitrary boundaries. The review also raised a concern absent from much of the literature: the effects of specific age thresholds in priority rules, where a patient just above the cutoff faces a dramatically different waitlist experience than one just below.28PubMed. The ethical debate over child priority in post-mortem organ allocation: A scoping review and practical-ethical outlook
In the United States, kidney allocation policy has evolved to try to balance these competing values. The system aims to match the expected longevity of the donor organ with the expected life span of the recipient, which in practice tends to favor younger patients for the highest-quality kidneys. But the process is incremental and contentious, with each revision reflecting new data and new priorities.29Pediatric Transplantation. Pediatric deceased donor renal transplantation: An approach to decision making I. Pediatric kidney allocation in the USA: The old and the new
Emerging Technologies
Two frontiers stand out. The first is machine perfusion, a technique that keeps a donor organ alive and functioning on a pump outside the body, rather than storing it on ice. A recent single-center case series demonstrated that normothermic machine perfusion could be adapted for pediatric-sized liver grafts from donors weighing less than 35 kilograms. Of 14 pediatric livers placed on the pump, 12 met viability criteria and were transplanted, with no patient deaths or episodes of primary nonfunction during early follow-up.30PubMed. Normothermic machine perfusion of pediatric liver allografts: A single-center case series In an even more striking demonstration, one team performed a first-in-human on-pump reduction of a pediatric donor liver: a whole liver was placed on a perfusion machine, surgically reduced to a smaller segment while still perfused and warm, and then transplanted into a two-month-old infant with acute liver failure.31Transplantation. Expanding Pediatric Liver Transplant Options: On-pump Split Reduction With Normothermic Machine Perfusion
The second frontier is xenotransplantation, the use of genetically engineered animal organs. The immature infant immune system, with its relative absence of anti-carbohydrate antibodies and reduced complement activity, makes infants potentially better candidates for pig organ transplants than adults. Researchers have proposed that genetically engineered pig hearts could be used as a bridge to allotransplantation in neonates with complex congenital heart disease who would otherwise die waiting for a human donor heart.32Pediatric Transplantation. The potential of genetically engineered pig heart transplantation in infants with complex congenital heart disease This is not yet clinical reality, but the same immune tolerance window that enables ABO-incompatible transplants in infants provides a biological rationale for attempting cross-species transplants in the youngest patients first.33PubMed Central. The immune system in infants: Relevance to xenotransplantation
Transplanting Before Birth
The most conceptually radical idea in the field is in utero hematopoietic stem cell transplantation: transplanting blood-forming stem cells into a fetus before birth. The theory is compelling. Normal fetal development includes a phase in which the immune system is actively tolerant, meaning that foreign cells introduced during this window might be accepted permanently without the need for myeloablation or lifelong immunosuppression.34JAMA. In Utero Hematopoietic Stem Cell Transplantation: A Status Report In practice, clinical success has been limited almost entirely to cases where the fetus already had a severe immune deficiency, meaning its immune system was too impaired to reject the graft. In fetuses with functional immunity, the maternal immune response and residual fetal immune barriers have prevented reliable engraftment so far.35PubMed Central. Maternal and Fetal Immune Response to in Utero Stem Cell Transplantation The gap between the theoretical promise and clinical results has kept this approach in the experimental phase for decades, though ongoing work on overcoming both fetal and maternal immune barriers continues.